

Addendum: The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

Anqi Shao¹ and David M. Owens^{1,2}

¹Department of Dermatology, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

²Department of Pathology and Cell Biology, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

Published:

Copyright: © 2024 Shao and Owens. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: This article received a publication fee waiver.

Original article: Oncotarget. 2023; 14:96–103. <https://doi.org/10.18632/oncotarget.28354>